LAVA Therapeutics N.V. Stock Price, News & Analysis

LAVA Therapeutics announced initial clinical data from its ongoing Phase 1/2a study of LAVA-1207 for treating therapy refractory metastatic castration-resistant prostate cancer (mCRPC). The results, presented at ASCO GU, show a favorable safety profile with no high-grade cytokine release syndrome. Preliminary signs of anti-tumor activity were noted, including stable disease in 8 out of 14 patients and PSA levels stabilizing or decreasing. The trial features a dose escalation up to 120 micrograms, with treatment duration ranging from 4 to 38 weeks.

LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company, announced that its CEO, Stephen Hurly, will present at the 2023 SVB Securities Global Biopharma Conference.

The presentation is scheduled for February 16, 2023, from 1:00 p.m. to 1:30 p.m. EST. A webcast will be available on the company's investor relations page and archived for 90 days post-event.

LAVA focuses on developing its proprietary Gammabody™ platform to create bispecific gamma-delta T cell engagers for cancer treatment, with notable pipeline candidates including LAVA-051 and LAVA-1207.

LAVA Therapeutics N.V. (Nasdaq LVTX) has appointed Dr. Charles Morris as Chief Medical Officer, effective February 6, 2023, succeeding Benjamin Winograd. Dr. Morris brings over 25 years of oncology experience, having held leadership roles at various biotech firms, including Celyad Oncology and Radius Health. His expertise in advancing oncology products is expected to enhance LAVA's Gammabody™ platform, aimed at treating various cancers with bispecific gamma-delta T cell engagers. The company is currently enrolling patients in clinical studies for its lead candidate, LAVA-051, and is optimistic about its potential to transform cancer treatment.

LAVA Therapeutics, a clinical-stage immuno-oncology company, announced that data from its Phase 1/2a study on LAVA-1207 will be presented at the ASCO GU Symposium in San Francisco from February 16-18, 2023. The presentation will focus on the early dose escalation of LAVA-1207, a bispecific gamma-delta T cell engager, in patients with therapy-refractory metastatic castration-resistant prostate cancer (mCRPC). The abstract (153) will be part of Poster Session A on February 16. LAVA aims to transform cancer treatment using its Gammabody™ platform and is also conducting trials with its lead candidate LAVA-051 for various hematologic malignancies.

LAVA Therapeutics announced the appointment of Peter A. Kiener, DPhil, and Mary E. Wadlinger to its Board of Directors, effective January 1, 2023. Kiener brings extensive experience in biologics and immunotherapy, having held leadership roles at multiple biopharmaceutical companies. Wadlinger has a strong background in human resources within the biotech sector. This transition follows Guido Magni's departure from the board, who contributed significantly since 2018. The new appointments aim to advance LAVA's strategy in developing bispecific gamma delta T cell engagers for cancer treatment.

LAVA Therapeutics, a clinical-stage immuno-oncology company, announced that CEO Stephen Hurly will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. The presentation will take place from 10:30 a.m. to 11:10 a.m. PST. Interested parties can access a webcast of the presentation on the LAVA Therapeutics investor relations website, with a replay available for 90 days. The company focuses on its proprietary Gammabody™ platform, developing bispecific gamma-delta T cell engagers targeting various cancers, including multiple myeloma.

LAVA Therapeutics (Nasdaq: LVTX) announced a poster presentation at the 64th ASH Annual Meeting showcasing initial data from its ongoing Phase 1/2a trial of LAVA-051. The study targets patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and multiple myeloma (MM).

The preliminary results indicate successful dose escalation to 200 µg without significant toxicity or cytokine release syndrome. The therapy demonstrated predictable pharmacokinetics and early signs of clinical activity, with ongoing dose escalations in the US and EU.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced key developments in its pipeline and financial results for Q3 2022. Notable highlights include the presentation of interim clinical data for LAVA-051 in treating relapsed or refractory chronic lymphocytic leukemia and multiple myeloma at the ASH Annual Meeting. Additionally, LAVA secured a $50 million upfront payment from Seagen for an exclusive worldwide license agreement on LAVA-1223, providing a cash runway beyond 2024. Research and license revenue for Q3 reached $15.3 million, up from $2.1 million in 2021.

LAVA Therapeutics, a clinical-stage immuno-oncology company focused on bispecific gamma delta T cell engagers, announced that CEO Stephen Hurly will present at the Jefferies London Healthcare Conference.

The presentation is scheduled for November 17, 2022, from 8:00 a.m. to 8:30 a.m. GMT (3:00 a.m. to 3:30 a.m. EST). A webcast will be available in the investor relations section of their website and archived for 90 days afterward.